ArticleThe Lancet. Respiratory medicine2020
Prevalence and attributable health burden of chronic respiratory diseases, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017.
Article in The Lancet. Respiratory medicine, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 5 registered trials, which are not on this map. Cited by 1,247 papers, 9 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
CENTR(AR): Lungs Moving
Value of Incentive Spirometry in Routine Management of COPD Patients and Its Effect on Diaphragmatic Function
Trajectories of FEV1 After Lung Transplantation: Determinants and Clinical Outcomes
Exploration and Study on the Identification of Various Pulmonary Diseases Using Volatile Organic Compounds Biomarkers in Human Exhaled Breath
Effectiveness of WearME System for FEV1/FVC, Respiration and Activity Biomarkers in COPD Patients
Who cites it
1,247 citing papers in PubMed, 9 syntheses or guidelines pooled it, 2,174 citations in OpenAlex.
- Biologic therapies targeting type 2 inflammation in chronic obstructive pulmonary disease: a systematic review and meta-analysis of randomised controlled trials.BMJ open respiratory research · 2026Pooled it
- Experiences of Individuals With Chronic Obstructive Pulmonary Disease and Their Caregivers During the Pandemic: A Systematic Review.Nursing open · 2026Pooled it
- COPD-patients' perspective on adherence to therapy and its integration into a systematic literature review.BMC pulmonary medicine · 2026Pooled it
- Global Economic and Social Burden of Chronic Obstructive Pulmonary Disease: A Systematic Review (2020-2024).International journal of chronic obstructive pulmonary disease · 2026Pooled it
- Unburdening healthcare systems through telenursing in chronic respiratory disease management: a systematic review.Frontiers in digital health · 2026Pooled it
- Effects of inspiratory muscle training on inspiratory muscle strength and exercise tolerance in patients with COPD: a meta-analysis and systematic review.Frontiers in medicine · 2026Pooled it
- Association between hypertension and impaired lung function among adults: A systematic review and meta-analysis.PloS one · 2026Pooled it
- Risk factors for hospital readmission in chronic obstructive pulmonary disease: a systematic review and meta-analysis.Frontiers in medicine · 2026Pooled it
- Effects of wearable devices on physical activity monitoring in pulmonary rehabilitation programs for chronic respiratory diseases: a systematic review and meta-analysis.Scientific reports · 2025Pooled it
- Visual feedback using electrical impedance tomography during inhalation therapy for chronic obstructive lung disease: a pilot study.Scientific reports · 2026Trial
- Exploring associations between maternal vitamin D-binding protein, vitamin D, and offspring asthma/recurrent wheeze.The American journal of clinical nutrition · 2026Trial
- A randomized controlled trial of adjunctive speleotherapy in asthma, COPD and long COVID.Scientific reports · 2026Trial
- Multi parameter respiratory training for pulmonary rehabilitation in AECOPD a randomized controlled trial.Scientific reports · 2026Trial
- Efficacy and Safety of Escitalopram in Alleviating Depression and Anxiety Symptoms in COPD Patients: A Randomized Double-Blind Placebo-Controlled Trial.International journal of chronic obstructive pulmonary disease · 2026Trial
- Cost-effectiveness of a self-management maintenance programme following pulmonary rehabilitation: a UK randomised controlled trial for patients with chronic obstructive pulmonary disease.BMJ open respiratory research · 2025Trial
- Aspirin Dosing for Secondary Prevention of Atherosclerotic Cardiovascular Disease in Chronic Obstructive Pulmonary Disease and Asthma: Insights From ADAPTABLE.Journal of the American Heart Association · 2025Trial
- Prevalence of abnormal spirometry and correlates of lung function decline among a population in rural Uganda.Journal of global health · 2026Article
- Chimeric antigen receptor T (CAR-T) cell therapy in non-oncological diseases.Signal transduction and targeted therapy · 2026Review
- The club cell circadian clock regulates temporal patterns in leukocyte trafficking in chronic allergic airways disease.Mucosal immunology · 2026Article
- Cardiovascular and mortality risks following COVID-19-related versus non-COVID-19-related chronic obstructive pulmonary disease exacerbations.Annals of the American Thoracic Society · 2026Article
1,187 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
Authors and funding
1 author at 4 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundPrevious attempts to characterise the burden of chronic respiratory diseases have focused only on specific disease conditions, such as chronic obstructive pulmonary disease (COPD) or asthma. In this study, we aimed to characterise the burden of chronic respiratory diseases globally, providing a comprehensive and up-to-date analysis on geographical and time trends from 1990 to 2017.
methodsUsing data from the Global Burden of Diseases, Injuries, and Risk Factors Study (GBD) 2017, we estimated the prevalence, morbidity, and mortality attributable to chronic respiratory diseases through an analysis of deaths, disability-adjusted life-years (DALYs), and years of life lost (YLL) by GBD super-region, from 1990 to 2017, stratified by age and sex. Specific diseases analysed included asthma, COPD, interstitial lung disease and pulmonary sarcoidosis, pneumoconiosis, and other chronic respiratory diseases. We also assessed the contribution of risk factors (smoking, second-hand smoke, ambient particulate matter and ozone pollution, household air pollution from solid fuels, and occupational risks) to chronic respiratory disease-attributable DALYs.
findingsIn 2017, 544·9 million people (95% uncertainty interval [UI] 506·9-584·8) worldwide had a chronic respiratory disease, representing an increase of 39·8% compared with 1990. Chronic respiratory disease prevalence showed wide variability across GBD super-regions, with the highest prevalence among both males and females in high-income regions, and the lowest prevalence in sub-Saharan Africa and south Asia. The age-sex-specific prevalence of each chronic respiratory disease in 2017 was also highly variable geographically. Chronic respiratory diseases were the third leading cause of death in 2017 (7·0% [95% UI 6·8-7·2] of all deaths), behind cardiovascular diseases and neoplasms. Deaths due to chronic respiratory diseases numbered 3 914 196 (95% UI 3 790 578-4 044 819) in 2017, an increase of 18·0% since 1990, while total DALYs increased by 13·3%. However, when accounting for ageing and population growth, declines were observed in age-standardised prevalence (14·3% decrease), age-standardised death rates (42·6%), and age-standardised DALY rates (38·2%). In males and females, most chronic respiratory disease-attributable deaths and DALYs were due to COPD. In regional analyses, mortality rates from chronic respiratory diseases were greatest in south Asia and lowest in sub-Saharan Africa, also across both sexes. Notably, although absolute prevalence was lower in south Asia than in most other super-regions, YLLs due to chronic respiratory diseases across the subcontinent were the highest in the world. Death rates due to interstitial lung disease and pulmonary sarcoidosis were greater than those due to pneumoconiosis in all super-regions. Smoking was the leading risk factor for chronic respiratory disease-related disability across all regions for men. Among women, household air pollution from solid fuels was the predominant risk factor for chronic respiratory diseases in south Asia and sub-Saharan Africa, while ambient particulate matter represented the leading risk factor in southeast Asia, east Asia, and Oceania, and in the Middle East and north Africa super-region.
interpretationOur study shows that chronic respiratory diseases remain a leading cause of death and disability worldwide, with growth in absolute numbers but sharp declines in several age-standardised estimators since 1990. Premature mortality from chronic respiratory diseases seems to be highest in regions with less-resourced health systems on a per-capita basis.
fundingBill & Melinda Gates Foundation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.